title: The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
abstract: Platelet characteristics, such as platelet dose, platelet source (apheresis vs pooled), platelet donor-recipient ABO compatibility, and duration of platelet storage, can affect posttransfusion platelet increments, but it is unclear whether these factors impact platelet transfusion efficacy on clinical bleeding. We performed secondary analyses of platelet transfusions given in the prospective randomized Platelet Dose Study, which included 1272 platelet-transfused hematology-oncology patients who received 6031 prophylactic platelet transfusions. The primary outcome of these analyses was time from first transfusion to first World Health Organization ≥ grade 2 bleeding. Platelet transfusion increments were assessed at 0.25 to 4 hours and 16 to 32 hours after platelet transfusion. There were 778 patients evaluable for analysis of time to bleeding. Adjusted models showed that randomized dose strategy, platelet source, ABO compatibility, and duration of storage did not predict this outcome. Platelet increments were generally higher for transfusions of apheresis platelets, ABO-identical platelets, and platelets stored 3 days versus 4 to 5 days. Thus, although platelet source, ABO compatibility, and duration of storage exert a modest impact on both absolute and corrected posttransfusion platelet increments, they have no measurable impact on prevention of clinical bleeding. This trial was registered at www.clinicaltrials.gov as #NCT00128713.
authors.affiliation: University of Pittsburgh and the Institute for Transfusion Medicine, Pittsburgh, PA 15213, USA. dtriulzi@itxm.org
authors.forename: Darrell J
authors.initials: DJ
authors.lastname: Triulzi
authors.forename: Susan F
authors.initials: SF
authors.lastname: Assmann
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Strauss
authors.forename: P M
authors.initials: PM
authors.lastname: Ness
authors.forename: John R
authors.initials: JR
authors.lastname: Hess
authors.forename: Richard M
authors.initials: RM
authors.lastname: Kaufman
authors.forename: Suzanne
authors.initials: S
authors.lastname: Granger
authors.forename: Sherrill J
authors.initials: SJ
authors.lastname: Slichter
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology; D000328:Adult; D001792:Blood Platelets / Q000166:cytology* / Q000276:immunology; D001793:Blood Preservation; D002648:Child; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D017713:Platelet Transfusion / Q000379:methods*; D011446:Prospective Studies; D013921:Thrombocytopenia / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System